News

November 2020

Brazil / ANVISA joins PIC/S

Geneva, 30 November 2020 :  The PIC/S Committee has invited Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) to join the PIC Scheme.

Brazil / ANVISA will become PIC/S’ 54th Participating Authority as from 1 January 2021. ANVISA submitted a complete membership application in October 2014. A paper assessment was carried out followed by an on-site assessment visit which took place in October 2019, after a reorganisation at ANVISA. The assessment report was finalised in the course of 2020. The Audit team recommended to the Committee to accept the PIC/S membership application of ANVISA. After endorsement by the PIC/S Sub-Committee on Compliance (SCC), the PIC/S Committee then unanimously decided by written procedure completed on 27 November 2020, on the participation of ANVISA in PIC/S.

This is the first time in PIC/S’ history that an assessment process is completed by written procedure rather than at a Committee meeting. This was due to the situation with Covid-19 which prevented a Committee meeting taking place in 2020. A special welcome will be given to ANVISA at the next PIC/S virtual Committee meeting in 2021.

November 2021

Concept Papers on the revision of EU-PIC/S GMP Annexes 4 & 5

Geneva, 10 November 2021: The PIC/S Working Group on Veterinary Medicinal Products (VMP), led by Grégory Verdier (France / ANSES), and the EMA GMP/GDP Inspectors Working Group have jointly developed two concept papers on the revision of Annex 4 (manufacture of veterinary medicinal products other than immunologicals) and Annex 5 (manufacture of immunological veterinary medicinal products) of the EU-PIC/S GMP Guide.

These concept papers are submitted to a joint PIC/S-EMA public consultation from 9 November 2021 until 9 January 2022 and can be downloaded on the PIC/S website (https://picscheme.org/en/publications?tri=draft#zone) as well as on the EMA website (https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice/gmp-gdp-inspectors-working-group#concept-papers,-reflection-papers-and-draft-guidelines-section)

Comments should be sent to ADM-GMDP@ema.europa.eu using the EMA template downloadable via the link provided in the Concept Papers by 9 January 2022.

September 2021

China / NMPA applies for PIC/S pre-accession

Geneva, 29 September 2021: On 24 September 2021, China’s National Medical Products Administration (NMPA) submitted an application for “pre-accession” to PIC/S. This is a voluntary but highly recommended assessment step that can be completed prior to submitting an application to become a PIC/S Participating Authority. The Pre-Accession Procedure provides up to 2 years to identify any gaps between PIC/S membership requirements and the system used by the interested Competent Authority. This step helps in understanding of PIC/S’ expectations in terms of membership and compliance to facilitate success in any future membership application under the PIC/S Accession Procedure.  You can find more information about the two steps in PIC/S’s Pre-Accession and Accession Procedures on our website.  As a next step, the PIC/S Committee will nominate a Rapporteur and one or several Co-Rapporteurs, who will manage and oversee NMPA’s pre-accession process.

August 2021

PIC/S Virtual Seminar 2021

Geneva, 2 August 2021: Registrations for the 2021 PIC/S Seminar on "GMP Assessment Approaches in Post COVID-19 Era" which will be hosted virtually from 9-11 November 2021 are now open (for Medicines Regulatory Authorities only). Deadline for registration is 3 October 2021.

For more information,  please contact the PIC/S Secretariat.

More

2021 Seminar on “GMP Assessment Approaches in Post COVID-19 Era"  

The Ministry of Food and Drug Safety (MFDS) of the Republic of Korea is pleased to announce that the 2021 PIC/S Virtual Seminar will be hosted by MFDS from 9 to 11 November 2021.

The Seminar on “GMP Assessment Approaches in Post COVID-19 Era” will consist of presentations, interactive panel discussions, and workshops for GMP Inspectors from around the world.

As the COVID-19 pandemic has put restrictions on GMP on-site inspections, various alternative GMP assessment approaches have been taken by Regulatory Authorities to ensure the quality of pharmaceuticals. As we face the post COVID-19 era, there is a need to explore the current and future status of these GMP assessment approaches. There is also a need to be prepared for the changes that will likely be seen in post COVID-19. Therefore, in this Seminar, we look forward to valuable presentations and discussions regarding different experiences in distant assessment from regulatory and industry experts; and regarding the status of GMP assessment based on reliance.

The Seminar is open to the participation of Inspectors from Medicines Regulatory Authorities around the world.

> For more information

July 2021

Adoption and Entry into force of PI 055-1 "COVID-19 Risk Assessment for Routine On-Site Inspections"

Geneva, 15 July 2021: PIC/S is pleased to announce that following its adoption by the PIC/S Committee on 30 June 2021, the guidance on “COVID-19 Risk Assessment for Routine On-Site Inspections” (PI 055-1) will enter into force on 15 July 2021. This guidance for inspectorates, which has been prepared by the PIC/S Working Group on Inspectors Safety, is available for downloading on the page “Publications”.

July 2021

Entry into Force of PI 054-1 PQS Recommendation

Geneva, 15 July 2021: PIC/S is pleased to announce the coming into force on 15 July 2021 of the PIC/S Recommendation document titled “How to Evaluate and Demonstrate the Effectiveness of the Pharmaceutical Quality System with regard to Risk-Based Change Management”, PI 054-1.  This document addresses two fundamental and inter-related elements of the PIC/S GMP Guide - PQS effectiveness and the management of changes. It provides practical guidance for GMP Inspectors in these areas, and the implementation of that guidance has the potential to ultimately lead to the more timely management of risks to product quality and patient safety, as well as better quality and manufacturing performance, continual improvement and innovation.  This serves the interest of patients and animals.

In addition to providing guidance for GMP Inspectors, the document provides the pharmaceutical industry with a ready-made solution for addressing a key aspect of ICH Q12 - the requirement to have an effective PQS that can support the risk-based management of post-approval changes when there is more flexible regulatory oversight of such changes in place.   

The input of industry representatives was considered during the development of this document and their contributions are gratefully acknowledged. 

To download this guidance (PI 054-1), please consult the page “Publications”.